Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies

  • Unicycive Therapeutics Inc UNCY announced key findings of UNI-494 efficacy from a preclinical study in Geographic Atrophy (GA).
  • UNI-494 is a mitochondrial potassium channel (mitochondrial KATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver, and ocular diseases. Mitochondrial dysfunction is implicated in Age-related Macular Degeneration (AMD) progression. 
  • GA is an advanced form of AMD. The company evaluated the effect of UNI-494 in preventing visual function loss in a rat model of GA.
  • The study evaluated four groups (n=8 per group): untreated, vehicle control, low dose of UNI-494, and high dose of UNI-494. 
  • Treatment of animals with the high dose of UNI-494 resulted in 150% and 200% improvement in contrast vision compared to vehicle and untreated animals.
  • The company says it is on track to initiate a Phase I study in healthy volunteers during the first quarter of 2023 in the U.K. following clearance by the Medicines and Healthcare products Regulatory Agency.
  • Price Action: UNCY shares are trading at $0.74 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!